Recombinetics
Recombinetics specializes in animal gene editing, focusing on biomedical research, regenerative medicine, and animal agriculture, with a significant role in xenotransplantation through its merger with Makana Therapeutics.
Services
Recombinetics specializes in animal gene editing and associated applied technologies. Their services span across biomedical research, regenerative medicine, and animal agriculture. Using a proprietary gene editing platform, they commercialize and deploy advanced technologies through various subsidiaries. Their expertise helps address complex challenges in multiple sectors by developing gene-edited animals for both biomedical and food animal markets.
Subsidiaries
Recombinetics operates several subsidiaries to leverage their gene editing technologies. Therillume focuses on precision medicine for brain tumors, utilizing cutting-edge genetic techniques. Acceligen uses precision breeding to enhance food animal health, welfare, and sustainability. These subsidiaries allow Recombinetics to apply their innovations in specialized areas, maximizing the impact of their gene editing platform across different fields.
Mergers and Collaborations
Recombinetics merged with Makana Therapeutics to work on solutions for the organ shortage crisis. This collaboration focuses on xenotransplantation, a method of transplanting animal organs into humans, which could significantly alleviate the shortage of human organs available for transplant. The merger combines the strengths of both companies to advance research and development in this critical area.
Innovation and Technology
Recombinetics holds a robust global patent portfolio, with 68 issued patents and over 190 additional applications filed. Their proprietary technologies include first-use and enabling patents in livestock gene editing using CRISPR and TALENs. This extensive patent portfolio underscores their leadership in gene editing innovation, supporting their commercial efforts and protecting their intellectual property in a competitive market.
Location
Recombinetics is located at 3388 Mike Collins Drive, Eagan, MN 55121. Their strategic location supports their operations and collaborations within the biotechnology and gene editing industries. Access to a robust local and national infrastructure enables them to continue advancing their research and business endeavors efficiently.